Cellectis (CLLS) News Today → Did you make $29,000 two days with AI options trades? (From Prosper Trading Academy) (Ad) Free CLLS Stock Alerts $2.49 -0.05 (-1.97%) (As of 03/18/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineEuropean Equities Traded in the US as American Depositary Receipts Open Week Lower in Monday Tradingmsn.com - March 11 at 2:04 PMCellectis (NASDAQ:CLLS) Share Price Crosses Below 50 Day Moving Average of $2.99marketbeat.com - February 27 at 4:34 AMCellectis S.A. (CLLS)finance.yahoo.com - February 24 at 2:02 PMCellectis S.A. ADRwsj.com - February 20 at 8:24 PMBaillie Gifford & Co. Has $1.84 Million Stock Holdings in Cellectis S.A. (NASDAQ:CLLS)marketbeat.com - February 18 at 7:21 AMCellectis (NASDAQ:CLLS) Stock Price Passes Above Fifty Day Moving Average of $3.02marketbeat.com - February 3 at 4:25 AMMonthly information on share capital and company voting rightsfinance.yahoo.com - February 3 at 1:54 AMEuropean Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, End Week Up 2.6%msn.com - January 26 at 6:11 PMCellectis draws down second tranche under EIB credit facilitymsn.com - January 16 at 9:30 PMCellectis announces the drawdown of the second tranche of €15 million under the credit facility agreement entered with the European Investment Bank (EIB)finance.yahoo.com - January 16 at 9:30 PMShort Interest in Cellectis S.A. (NASDAQ:CLLS) Decreases By 19.9%marketbeat.com - December 31 at 5:18 PMCellectis Reports Results from Shareholders Meeting Held on December 22, 2023finance.yahoo.com - December 22 at 7:58 PMCellectis - ADR (CLLS) Price Target Increased by 20.85% to 11.75msn.com - December 16 at 2:06 PMCellectis S.A. (NASDAQ:CLLS) Short Interest Updatemarketbeat.com - December 15 at 12:57 AMCellectis’ Shareholders Meeting to be Held on December 22, 2023finance.yahoo.com - November 17 at 7:47 PMCellectis Announces the execution of the Subsequent Investment Agreement with AstraZenecafinance.yahoo.com - November 15 at 9:32 AMCellectis SA ADR CLLSmorningstar.com - November 12 at 2:21 PMCellectis S.A. (NASDAQ:CLLS) Q3 2023 Earnings Call Transcriptfinance.yahoo.com - November 8 at 4:18 PMAnalysts Offer Insights on Healthcare Companies: Cellectis SA (CLLS), Agenus (AGEN) and OrthoPediatrics (KIDS)markets.businessinsider.com - November 8 at 3:28 AMCellectis Non-GAAP EPS of -$0.58, revenue of $1.88Mseekingalpha.com - November 6 at 9:13 PMEarnings Preview: Cellectisbenzinga.com - November 3 at 8:38 PMCellectis to Present Preliminary Results of NATHALI_01 and Updated Results of the BALLI_01 Phases I Trials at the American Society of Hematology (ASH) 65th Annual Meetingfinance.yahoo.com - November 2 at 5:55 PMCellectis - ADR (CLLS) Price Target Increased by 11.03% to 11.29msn.com - November 1 at 8:37 PMCellectis to Report Third Quarter 2023 Financial Results on November 6, 2023finance.yahoo.com - November 1 at 8:37 PMCellectis Announces Collaboration Agreement With AstraZeneca; To Receive Up To $245 Mlnmarkets.businessinsider.com - November 1 at 3:37 PMBiotech Shares Soar After AstraZeneca Stake & Research Collaborationtheglobeandmail.com - November 1 at 3:37 PMWhy Is Cancer Player Cellectis Stock Trading Over 100% Higher Today?msn.com - November 1 at 3:37 PMAstraZeneca to invest $245m in French biotech company Cellectismsn.com - November 1 at 10:36 AMWhy Is Cellectis (CLLS) Stock Up 175% Today?markets.businessinsider.com - November 1 at 10:36 AMEuropean Equities Traded in the US as American Depositary Receipts Remain Relatively Flat in Tuesday Tradingmsn.com - October 31 at 5:52 PMCellectis Presents Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meetingfinance.yahoo.com - October 31 at 5:52 PMBlueprint Medicines earnings: here's what Wall Street expectsmarkets.businessinsider.com - October 25 at 6:42 PMCellectis to Present Pre-Clinical Data on HSPC Gene Therapy Program and Comprehensive Analysis of TALE-BE at the ESGCT 30th Annual Congressfinance.yahoo.com - October 24 at 7:23 PMTelecoms Stocks Lift European Equities Traded in the US as American Depositary Receipts Mondaymsn.com - October 16 at 3:36 PMEuropean Equities Traded in the US as American Depositary Receipts Decline Friday But End Week Up Nearly 2%msn.com - October 13 at 8:41 PMCellectis and Imagine Institute Publish A Proof-Of-Concept Study of a Gene Surgery Candidate to Treat Activated Phosphoinositide 3-Kinase Δ Syndrome Type 1 (APDS1)finance.yahoo.com - October 12 at 5:10 PMThese 2 “Strong Buy” Penny Stocks Could Gain Over 500%, Says Bairdmsn.com - October 3 at 2:21 PMCellectis - ADRmoney.usnews.com - September 22 at 3:45 PMJonesTrading Sticks to Their Hold Rating for Cellectis SA (CLLS)markets.businessinsider.com - August 8 at 8:05 PMCellectis Provides Full Report for Second Quarter 2023 Financial Resultsfinance.yahoo.com - August 8 at 10:05 AMCellectis Provides Business Updates and Preliminary Financial Results for Second Quarter 2023finance.yahoo.com - August 3 at 8:22 PMCellectis - ADR (CLLS) Price Target Increased by 7.35% to 11.62msn.com - August 1 at 10:26 PMCellectis (NASDAQ: CLLS)fool.com - July 29 at 4:49 AMBaillie Gifford & Co. Has $3.17 Million Stock Position in Cellectis S.A. (NASDAQ:CLLS)marketbeat.com - July 28 at 10:49 AMCellectis to Report Second Quarter 2023 Financial Results on August 3, 2023finance.yahoo.com - July 28 at 8:47 AMCellectis Appoints Dr. Cécile Chartier, Ph.D. to its Board of Directorsfinance.yahoo.com - July 12 at 6:56 PMCellectis S.A. Reports Results from Annual Shareholders’ General Meeting Held on June 27, 2023finance.yahoo.com - June 28 at 5:05 PMCellectis Presents Updated Clinical and Translational Data on BALLI-01 at the European Hematology Association (EHA) 2023finance.yahoo.com - June 9 at 8:17 PMCellectis Presents Updated Clinical and Translational Data on BALLI-01 at the European Hematology Association (EHA) 2023finance.yahoo.com - June 9 at 8:17 PMCellectis Publishes an Article in Cancer Immunology Research Demonstrating Preclinical Evidence of UCART20x22 Product Candidate to Target a Broad Spectrum of Patients with B-cell Malignanciesfinance.yahoo.com - May 31 at 7:41 PM Get Cellectis News Delivered to You Automatically Sign up to receive the latest news and ratings for CLLS and its competitors with MarketBeat's FREE daily newsletter. Email Address They said crypto was dead. It went up 100X. (Ad)Bitcoin’s haters are out again. Despite the price doubling in the last six months alone… That hasn’t stopped the experts from piling on. Warren Buffett’s right-hand man Charlie Munger called crypto investors “idiots” in one of his last interviews. JPMorgan CEO Jamie Dimon, recently called Bitcoin a “pet rock” and “a hyped-up fraud.” But when it comes to cryptos, these are exactly the people you shouldn’t listen to. They’ve predicted crypto’s demise for years. There are five coins you must take a look at right away. CLLS Media Mentions By Week CLLS Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CLLS News Sentiment▼0.640.64▲Average Medical News Sentiment CLLS News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CLLS Articles This Week▼11▲CLLS Articles Average Week Get Cellectis News Delivered to You Automatically Sign up to receive the latest news and ratings for CLLS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: MOLN News XFOR News BLUE News ZURA News SGMO News DBVT News BCAB News VXRT News GNFT News CVM News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CLLS) was last updated on 3/18/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial MetalsLike Tiny Crypto Retirement FundsCrypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThe world’s greatest investmentPorter & CompanyForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingBill Gates Bets on $15 Trillion BonanzaWeiss RatingsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cellectis S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.